Major clinical trials of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and RAAS inhibitors in patients with diabetes, diabetic cardiomyopathy, and COVID-19: Cardiovascular and metabolic outcomes. This evidence concerns the gene SLC5A2 and diabetes mellitus.